NCT03041311 · MORE INFO

Limitations, agreements, and source contact

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC · Source last updated 2025-09-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: Limitation of the trial is small numbers of subjects, since it is a Phase 2 clinical trial. Small sample size may have reduced the ability to observe statistically significant treatment effects on secondary myelopreservation measures (i.e. occurrence of FN AEs, infections and antibiotics usage).

point Of Contact

email: clinicalinfo@g1therapeutics.com
organization: G1 Therapeutics, Inc.
phone: 919-213-9835
title: Clinical Trial Info.

Complete source fields

certain Agreement

pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: Limitation of the trial is small numbers of subjects, since it is a Phase 2 clinical trial. Small sample size may have reduced the ability to observe statistically significant treatment effects on secondary myelopreservation measures (i.e. occurrence of FN AEs, infections and antibiotics usage).

point Of Contact

email: clinicalinfo@g1therapeutics.com
organization: G1 Therapeutics, Inc.
phone: 919-213-9835
title: Clinical Trial Info.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice